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lasma Level of Oxidized
ow-Density Lipoprotein Is an Independent
eterminant of Coronary Macrovasomotor and
icrovasomotor Responses Induced by Bradykinin
etsuya Matsumoto, MD, Hiroyuki Takashima, MD, Naoto Ohira, MD, Yasuhiro Tarutani, MD,
o Yasuda, MD, Tetsunobu Yamane, MD, Shinro Matsuo, MD, Minoru Horie, MD
tsu, Japan
OBJECTIVES We examined the relationship between coronary endothelium-dependent vasodilation in
response to bradykinin (BK) and plasma levels of oxidized low-density lipoprotein (oxLDL)
in subjects with normal coronary arteries.
BACKGROUND It is unclear whether the plasma oxLDL level is a determinant of coronary endothelial
function. Bradykinin plays an important role in regulating resting coronary tone and
flow-mediated coronary vasomotion.
METHODS Coronary blood flow (CBF) in the left anterior descending (LAD) coronary artery was
assessed by quantitative angiography and a Doppler flow wire in 94 consecutive subjects with
normal coronary arteries. The plasma oxLDL level was measured by enzyme-linked
immunosorbent assay using DLH3R, a specific antibody against oxLDL.
RESULTS Plasma levels of oxLDL in diabetic subjects (n  13) were higher than those in non-diabetic
subjects (n  81). Plasma levels of oxLDL correlated with body mass index (BMI).
Bradykinin at doses of 0.2, 0.6, and 2.0 g/min caused dose-dependent increases in diameter
and CBF in the LAD coronary artery. By a univariate analysis, oxLDL levels significantly
correlated with epicardial (r  0.30, p  0.0001) and resistant (r  0.36, p  0.003)
coronary vasodilator responses to BK at 2.0 g/min, whereas total cholesterol, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides were not
associated with these coronary responses. In a stepwise multivariate analysis, oxLDL levels
were significantly correlated with epicardial and resistant coronary vasomotor responses to
BK, independent of age, gender, smoking status, other lipid levels, BMI, hypertension, and
diabetes.
CONCLUSIONS The plasma level of oxLDL is an appropriate surrogate for assessing coronary endothelial-
dependent vasomotor function as estimated by responses to BK compared with conventional
risk factors for atherosclerosis. (J Am Coll Cardiol 2004;44:451–7) © 2004 by the
















coronary endothelial vasomotor function is frequently im-
aired in the presence of coronary risk factors such as
ypercholesterolemia, hypertension, diabetes mellitus, and
moking (1–3). Several lipid parameters affect coronary
ndothelial function (2,4,5). However, low-density lipopro-
ein (LDL) cholesterol has not always been shown to have
n effect in multivariate analysis. Oxidized low-density
ipoprotein (oxLDL) may be an important modulator of
itric oxide (NO) bioavailability and is a hallmark of
therogenesis (6,7). Early in vitro studies indicated that
xLDL cholesterol, but not LDL cholesterol, contributes to
ndothelial dysfunction by enhancing the degradation and
nhibiting the synthesis of NO (8 –10). Cholesterol-
owering therapy improves coronary or forearm endothelial
unction (11,12).
There is accumulating evidence that coronary endothelial
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wccepted March 30, 2004.unction is associated with future cardiovascular events and
he progression of coronary artery disease (CAD) (13,14). It
as been shown that plasma levels of oxLDL were elevated
n patients with acute coronary syndrome and stable CAD
15,16). Nevertheless, the clinical importance of circulating
xLDL levels on coronary endothelial function has been
oorly analyzed.
Bradykinin (BK) plays an important role in regulating
esting coronary tone and flow-mediated coronary vasomo-
ion (17). Bradykinin causes endothelium-dependent coro-
ary vasodilation through the production of NO, prostacy-
lin, and endothelium-dependent hyperpolarizing factor
18). Recently, we reported that BK stimulates the release of
issue plasminogen activator as well as NO in human
oronary circulation (19). At present, there are no data
vailable regarding circulating parameters that may be
esponsible for BK-induced vasomotor responses in the
oronary macrocirculation and microcirculation.
Thus, the present study was performed to examine
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Oxidized LDL and Coronary Endothelial Function July 21, 2004:451–7ndependent determinant of BK-induced vasomotor re-
ponses of coronary conduit and resistance vessels compared
ith traditional coronary risk factors.
ETHODS
tudy patients. The study population consisted of 94
onsecutive patients undergoing routine diagnostic cathe-
erization and an assessment of coronary endothelial func-
ion for the evaluation of chest pain or myocardial ischemia
n an electrocardiogram.
The study protocols were approved by the Ethical Com-
ittee on Human Research of our institution, and written
nformed consent was obtained from all of the patients.
atients with myocardial infarction, congestive heart failure,
ardiomyopathy, valvular heart disease, coronary vasospastic
ngina, or organic stenosis (more than 25%) of coronary
rteries were excluded from the study.
Smokers refrained from smoking for at least seven days
efore the present study to rule out the direct effects of oxidants
ontained in cigarette smoke. All vasoactive medications,
ncluding calcium channel blockers, nitrates, -blockers, and
ngiotensin-converting enzyme inhibitors, as well as antioxi-
ants, including statin and probucol, were discontinued for at
east 48 h before the study. Smokers included subjects with a
urrent history of tobacco use for more than one year. Subjects
ere considered to have hypertension if they had a blood
ressure level of 140/90 mm Hg or more or if they were being
reated. Subjects were considered to be diabetic if they had a
asting blood glucose level of 140 mg/dl or more or if they were
lready being treated. Body mass index (BMI) was calculated
s weight in kilograms divided by the square of height in
eters (kg/m2).
rotocol. Right and left cardiac catheterization was per-
ormed between 9 AM and 10 AM in the fasting state. After a
iagnostic coronary angiographic study, a 0.014-inch Doppler-
ipped guide wire (Jometrics FloWire; JoMed Inc., Rancho
ordova, California) was advanced through the Judkins cath-
ter, as previously reported (19,20). The wire tip was posi-
ioned at the area between the proximal and middle segments
f the left anterior descending (LAD) coronary artery that was
ree of any major branches within 1 cm from the tip, which
ermitted the measurement of an adequate blood flow velocity.
ll drugs were infused directly into the left main coronary
Abbreviations and Acronyms
BK  bradykinin
BMI  body mass index
CAD  coronary artery disease
CBF  coronary blood flow
HDL  high-density lipoprotein
LAD  left anterior descending
LDL  low-density lipoprotein
NO  nitric oxide
oxLDL  oxidized low-density lipoproteinrtery via a 3-F coronary-infusion catheter (Cordis Endovas- lular Systems Inc., Miami, Florida) at infusion rates ranging
etween 0.5 and 1 ml/min.
Baseline coronary angiography and measurement of cor-
nary blood flow (CBF) velocity were performed, and
ubsequently, BK-induced vasodilation was estimated by
ose–response curves obtained with incremental 2-min
ntracoronary infusions of BK. Coronary angiography and
easurement of CBF velocity were performed after each
nfusion. Bradykinin was started at 0.2 g/min, and then
ncreased to 0.6 and 2.0 g/min. After completing the
rotocol with the intracoronary injection of BK, we waited
or at least 10 min, by which time the coronary diameter and
BF velocity had returned to the baseline values. Finally,
itroglycerin was given at 250 g into the left coronary
rtery over 20 s. Maximal epicardial coronary vasodilation
as measured after the infusion of nitroglycerin. Coronary
ngiography was performed at 2 min after the infusion of
itroglycerin. During the study, phasic and mean arterial
ressures, heart rate, and 12-lead electrocardiograms were
ontinuously monitored using a polygraph system (Nihon-
ohden Kogyo Co., Tokyo, Japan).
uantitative coronary angiography and measurement of
BF. Coronary cineangiograms were recorded using a Phil-
ps cineangiographic system (Philips Medical Systems, Tokyo,
apan). The change in diameter of the LAD coronary artery
as measured in a vessel segment 5 mm beyond the tip of the
oppler wire. Coronary angiograms were taken in the right
audal anterior oblique or right cranial anterior oblique posi-
ion with adequate angulation to allow for clear visualization of
he left coronary artery. Coronary angiograms were analyzed by
uantitative coronary angiography using a Cardiovascular
easurement System (QCA-CMS; MEDIS Medical Imag-
ng Systems, Leiden, The Netherlands). Measurements were
ade three times, and the average value was used for analysis.
eak CBF velocity was continuously monitored using a fast
ourier transform-based spectral analyzer (FloMap, Cardio-
etrics Inc., Mountain View, California). Coronary blood
ow was calculated as  average peak CBF velocity 0.125
(arterial diameter)2 . Vessel diameter and CBF velocity were
nalyzed by investigators blinded to the sequence of interven-
ions and the laboratory data.
reparation of BK. Bradykinin (Sigma Chemical Co.,
okyo, Japan) was diluted with physiologic saline at a
oncentration of 2 g/ml and sterilized at the Pharmacy
epartment, Shiga University of Medical Science Hospital.
ssay procedure for oxLDL and other lipids. Blood for
easuring the plasma level of oxLDL was placed into a plain
ube and centrifuged at 3,000 rpm for 15 min at 4°C. The
esulting plasma was stored at 4°C until the assay. Plasma
xLDL levels were measured using a specific immunometric
ssay for human oxLDL using an enzyme-linked immunosor-
ent assay kit (Kyowa Medex Co., Tokyo, Japan) (21), which
sed a modification of a method previously reported. Briefly,
his assay system uses two antibodies against human oxLDL,
ne a monoclonal antibody against oxidized phosphatidylcho-
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July 21, 2004:451–7 Oxidized LDL and Coronary Endothelial Functionpolipoprotein B, and measures oxLDL by sandwiching it
etween the two antibodies. Total cholesterol, high-density
ipoprotein (HDL) cholesterol, triglycerides and LDL choles-
erol were measured using enzymatic assays.
tatistical analysis. Data are expressed as the mean value 
EM. Unpaired Student t test was used for comparison of
ontinuous variables. Univariate and stepwise multivariate
inear regression analyses were used to detect independent
redictors of epicardial and resistant coronary vasodilation
nduced by BK (StatView version 5.0). A value of p 0.05 was
onsidered statistically significant.
ESULTS
ubject characteristics. The baseline characteristics of the
tudy group are shown in Table 1. The study population
ndergoing coronary angiography was predominantly male
nd older, and had a combination of risk factors that
equired cardiac medication.
lasma levels of oxLDL. Plasma levels of oxLDL in
iabetic subjects were higher (21.6  0.7 IU/ml, range 8.2
o 52.5 IU/ml) than those in non-diabetic subjects (12.9 
.6 IU/ml, range 2.4 to 44.6 IU/ml, p  0.0002) (Fig. 1,
eft). Plasma levels of oxLDL correlated with BMI (r 
able 1. Clinical Characteristics
ge (yrs) 58  1 (33–79)
ender (male/female) 68/26
moking status (%) 42 (45%)
ypertension (%) 30 (32%)
iabetes mellitus (%) 13 (14%)
ody mass index (kg/m2) 23.5  3.2 (16.7–34.0)
otal cholesterol (mg/dl) 188  4 (112–271)
riglycerides (mg/dl) 126  6 (30–343)
DL cholesterol (mg/dl) 46  1 (21–105)
DL cholesterol (mg/dl) 121  3 (49–195)
xidized LDL (U/ml) 13.8  0.9 (2.4–52.5)
ata are presented as mean  SE (range) or number (%) of subjects.
HDL  high-density lipoprotein; LDL  low-density lipoprotein.
igure 1. Effects of diabetes mellitus (DM) and body mass index (BMI) on
lasma levels of oxidized low-density lipoprotein (LDL). *p  0.0002
ersus the non-diabetic subjects. Values represent mean  SEM. Open
ircles represent non-diabetic subjects; closed circles represent diabetic
ubjects..21, p  0.05) (Fig. 1, right; Table 2). However, there was
o significant difference between diabetic and non-diabetic
ubjects with regard to BMI (24.8  1.0 vs. 23.3  0.3
g/m2). As shown in Table 2, plasma levels of oxLDL did
ot correlate with levels of total cholesterol, LDL choles-
erol, HDL cholesterol, or triglycerides, and were indepen-
ent of age, gender, smoking status, and hypertension (n 
4, respectively).
oronary vasomotor responses to BK and plasma levels
f oxidized LDL. Intracoronary infusion of BK (0.2, 0.6,
nd 2.0 g/min) caused dose-dependent increases in epi-
ardial coronary diameter and CBF (Table 3) without
ignificantly changing the arterial pressure or heart rate in
ny of the patients. The mean value of epicardial coronary
asodilation induced by nitroglycerin (250 g) was 23.0 
.7% in all of the patients.
In simple linear regression analyses, increases in epicar-
ial coronary diameter and CBF in response to BK (0.2, 0.6,
nd 2.0 g/min) showed significant negative correlations
ith plasma levels of oxLDL, respectively (n  94) (Table
). As shown in Figure 2, increases in epicardial coronary
iameter and CBF in response to BK (2.0 g/min) showed
ignificant negative correlations with plasma levels of ox-
DL. As shown in Figure 3, increases in epicardial coronary
iameter and CBF in response to BK (2.0 g/min) were not
orrelated with plasma levels of LDL cholesterol. The
picardial coronary vasodilation induced by nitroglycerin
able 2. Correlations Between Plasma Oxidized LDL Level
nd Other Parameters
r p Value
ge (yrs) 0.111 0.2857
ender (male  1) 0.15 0.1477
moking (yes  1) 0.085 0.4147
iabetes mellitus (yes  1) 0.377 0.0002
ypertension (yes  1) 0.091 0.3825
MI (kg/m2) 0.205 0.0475
otal cholesterol (mg/dl) 0.125 0.2314
riglycerides (mg/dl) 0.09 0.3864
DL cholesterol (mg/dl) 0.071 0.4986
DL cholesterol (mg/dl) 0.182 0.0797
MI  body mass index; HDL  high-density lipoprotein; LDL  low-density
ipoprotein.
able 3. Correlations Between Plasma oxLDL Levels and
oronary Vasomotor Responses to Bradykinin
Mean  SE r p Value
ncreases in epicardial
coronary diameter (%)
BK (0.2 g/min) 10.4  0.9 0.253 0.0137
BK (0.6 g/min) 15.9  1.2 0.308 0.0025
BK (2.0 g/min) 21.8  1.4 0.352 0.0005
ncreases in coronary
blood flow (%)
BK (0.2 g/min) 87.5  6.8 0.262 0.0108
BK (0.6 g/min) 162.5  10.1 0.362 0.0003
BK (2.0 g/min) 258.9  12.3 0.452 0.0001
ata are presented as mean  SE.
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p  0.07, n  94).
As shown in Table 4, epicardial coronary vasodilation
nduced by BK (2.0 g/min) was associated with diabetes
ellitus and BMI but was not correlated with age, gender,
moking status, or hypertension (n  94, respectively). The
picardial coronary vasodilation induced by BK (2.0 g/
in) was not correlated with plasma levels of cholesterol,
DL cholesterol, HDL cholesterol, or triglycerides (n 
4, respectively). In a stepwise multivariate analysis, the
lasma oxLDL level and BMI were significant independent
eterminants of the epicardial coronary vasodilation in-
uced by BK (2.0 g/min) (Table 4).
As shown in Table 5, the increases in CBF induced by
K (2.0 g/min) were associated with hypertension, diabe-
es mellitus, and BMI but were not correlated with age,
ender, or smoking status (n  94, respectively). The
ncreases in CBF induced by BK (2.0 g/min) were also not
orrelated with plasma levels of cholesterol, LDL choles-
erol, HDL cholesterol, or triglycerides (n  94, respec-
ively). In a stepwise multivariate analysis, the plasma
xLDL level and hypertension were significant independent
Figure 2. Relationship between plasma oxidized low-density lipoproteinFigure 3. Relationship between plasma low-density lipoprotein (LDL) cholesteeterminants of the increases in CBF induced by BK (2.0
g/min) (Table 5).
ISCUSSION
he present study is the first to demonstrate that the plasma
evel of oxLDL, but not conventional lipid parameters, is
ignificantly correlated with coronary macrovasomotor and
icrovasomotor responses induced by BK. Thus, the
lasma level of oxLDL may provide useful information for
redicting endothelial dysfunction underlying the progres-
ion of CAD and future cardiovascular events compared
ith conventional lipid parameters.
lasma level of oxLDL. In the present study, plasma levels
f oxLDL in diabetic patients were higher than those in
on-diabetic patients. Factors that may promote LDL
xidation in diabetic patients include antioxidant deficien-
ies, increased production of reactive oxygen species, and
rotein glycation. The plasma oxLDL level correlated with
MI but not with conventional lipid parameters, age,
ender, or smoking status. Obesity often coexists with
iabetes, but BMI did not differ between diabetic and
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July 21, 2004:451–7 Oxidized LDL and Coronary Endothelial Functionon-diabetic patients. Keaney et al. (23) recently reported
hat obesity, as measured by BMI, is independently associ-
ted with oxidative stress in the Framingham Heart Study.
The clinical importance of circulating oxLDL has not
een established, although oxLDL is involved in atherogen-
sis by inducing smooth muscle cell proliferation and
mooth muscle foam cell generation (6,7). Recent reports
ave shown that the plasma level of oxLDL was associated
ith the severity of acute coronary syndromes and CAD
15,16,24). Nevertheless, it is unclear whether plasma levels
f oxLDL may be associated with coronary vasomotor
eactivities in subjects with angiographically normal coro-
ary arteries. Several methods are available for estimating
xidative stress, but there are few appropriate assays that are
ensitive and specific for oxLDL. A monoclonal antibody,
LH3R (22), reacts with oxLDL but not with native,
cetylated, or malondialdehyde-treated LDL. Using this
robe, we reported that the plasma level of oxLDL is a
seful marker of oxidative stress in patients with heart
ailure (25). Further studies are needed to elucidate the
echanisms underlying the increase in circulating oxLDL
evels.







Gender (male  1) 0.117
Smoking (yes  1) 0.1
Diabetes mellitus (yes  1) 0.283
Hypertension (yes  1) 0.178
BMI (kg/m2) 0.327
Total cholesterol (mg/dl) 0.078
Triglycerides (mg/dl) 0.12
HDL cholesterol (mg/dl) 0.0069
LDL cholesterol (mg/dl) 0.008
Oxidized LDL (U/ml) 0.352
Abbreviations as in Table 2.







Gender (male  1) 0.057
Smoking (yes  1) 0.048
Diabetes mellitus (yes  1) 0.284
Hypertension (yes  1) 0.246
BMI (kg/m2) 0.263
Total cholesterol (mg/dl) 0.061
Triglycerides (mg/dl) 0.048
HDL cholesterol (mg/dl) 0.026
LDL cholesterol (mg/dl) 0.103
Oxidized LDL (U/ml) 0.452Abbreviations as in Table 2.xLDL level and coronary vasomotor response to BK.
n the present study, oxLDL levels but not other lipid
arameters correlated inversely and significantly with epicardial
nd resistant coronary vasodilation induced by BK. Bradykinin
egulates the resting tone and flow-mediated vasodilation in
uman coronary circulation (17). To investigate whether the
xLDL level is an independent determinant of coronary
asomotor responses to BK, a multivariate analysis was per-
ormed in which conventional coronary risk factors were
ntered as independent variables. We demonstrated that the
xLDL level, but not other lipid parameters, is an independent
nd powerful determinant of coronary macrovasomotor and
icrovasomotor responses to BK. Traditional coronary risk
actors such as hypercholesterolemia, hypertension, diabetes
ellitus, and cigarette smoking have been shown to contribute
o endothelial dysfunction in coronary and peripheral vessels,
nd these effects are not limited to atherosclerotic sites (1–3).
icotinamide adenine dinucleotide/nicotinamide adenine
inucleotide phosphate–mediated superoxide production may
ccount for endothelial dysfunction and the increased risk for
ardiovascular events in hypertensive patients (26). Non-
nsulin-dependent diabetes mellitus may cause endothelial
ysfunction through hyperglycemia, hyperinsulinemia, and
s of Epicardial Coronary Vasomotor
alue
Multivariate











005 0.484 (0.156) 0.0026
s of Resistance Coronary Vasomotor
alue
Multivariate
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auses coronary microvascular responses to BK and that dia-
etes mellitus is related to coronary macrovascular or micro-
ascular responses to BK.
The present study showed that BMI had an independent
ffect on coronary macrovasomotor responses to BK even
fter a multivariate analysis of conventional coronary risk
actors. It has recently been shown that BMI is an important
eterminant of CBF responses to acetylcholine in patients
ith normal or mildly diseased coronary arteries (28) and of
orearm blood flow responses to BK in healthy subjects (29).
rachial artery vasodilation induced by acetylcholine is
lunted in obese subjects, and this attenuated response is
eversed by vitamin C, suggesting that oxidative stress may
ontribute to endothelial dysfunction in human obesity (30).
Long-term cigarette smoking impairs endothelium-
ependent coronary and forearm vasodilation via increased
xidant stress (31,32). Thus, it is possible that coronary
esponses to BK and the plasma level of oxLDL may have
een normalized by the cessation of smoking before the
resent study.
Early studies showed that the level of total cholesterol
as inversely related to endothelium-dependent vasodi-
ation, regardless of the presence or absence of CAD
1,2). On the other hand, in vitro animal experiments
howed that an increase in oxLDL, but not native LDL
holesterol, causes endothelial dysfunction by inhibiting
he synthesis and enhancing the degradation of NO
8 –10). It has been shown that LDL size, triglycerides,
nd HDL cholesterol contribute to endothelium-
ependent vasomotor responses (33). In the present
tudy, the ranges of conventional lipid parameters may
ave been relatively narrow.
Recent studies have shown that abnormal coronary vasore-
ctivity can predict the progression of atherosclerotic disease
nd increased cardiovascular risk in patients at risk for CAD
13,14). Heitzer et al. (34) demonstrated that increased vascu-
ar oxidative stress may play an important role in mechanisms
or endothelial dysfunction and in the pathogenesis of cardio-
ascular events. Therefore, the plasma level of oxLDL could be
more useful predictor of cardiovascular events than conven-
ional coronary risk factors.
tudy limitations. Some patients received medications
uch as statins, probucol, calcium antagonists, angiotensin-
onverting enzyme inhibitors, or angiotensin-1 receptor
ntagonists before the study. These agents have been shown
o have beneficial effects on endothelial function, but the
resent study failed to address the beneficial effects of these
rugs (data not shown). Thus, we must further examine the
ffects of pharmacologic intervention on the plasma level of
xLDL and endothelial function.
Antibodies against oxLDL recognize different epitopes of
omplex structures formed during the oxidation of lipopro-
eins. The accurate quantitation of oxLDL will be achieved
hen the epitopes are better delineated.
In conclusion, the present study showed that the plasmaevel of oxLDL is an independent determinant of endothe-
ial function in coronary macrocirculation and microcircu-
ation in comparison with conventional lipid parameters.
ased on the concept that endothelial dysfunction precedes
ardiovascular events, measurement of the plasma oxLDL
evel may provide useful information for predicting future
ardiovascular events.
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